MR imaging evaluation of cardiovascular risk in metabolic syndrome

Radiology

Volumn 264, Issue 1, 2012, Pages 21-37

  Van Der Meer, Rutger W ^a   Lamb, Hildo J ^a   Smit, Johannes W A ^a   De Roos, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL OBESITY; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DOPPLER FLOWMETRY; EARLY DIAGNOSIS; FATTY LIVER; HUMAN; IMAGE ANALYSIS; METABOLIC SYNDROME X; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERICARDIAL ADIPOSITY; PERICARDIAL DISEASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; ULTRASOUND; WAIST CIRCUMFERENCE;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; MAGNETIC RESONANCE IMAGING; METABOLIC SYNDROME X; RISK; RISK FACTORS;

EID: 84862696466     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12110772     Document Type: Review

References (139)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143-3421.
2. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009;(13):1-7.
3. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303(3):235-241.
4. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120(16):1640-1645.
5. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006;47(6):1093-1100.
6. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112(20):3066-3072. (Pubitemid 43113437)
7. Ding EL, Smit LA, Hu FB. The metabolic syndrome as a cluster of risk factors: is the whole greater than the sum of its parts?: comment on "The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis". Arch Intern Med 2010;170(5):484-485.
8. Grundy SM. Does the metabolic syndrome exist? Diabetes Care 2006;29(7):1689-1692; discussion 1693-1696.
9. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28(9):2289-2304. (Pubitemid 41242486)
10. Diamant M, Lamb HJ, Groeneveld Y, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003;42(2):328-335. (Pubitemid 36851426)
11. Hammer S, Snel M, Lamb HJ, et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 2008;52(12):1006-1012.
12. van der Meer RW, Rijzewijk LJ, de Jong HW, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009; 119(15):2069-2077.
13. Kabir M, Catalano KJ, Ananthnarayan S, et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 2005;288(2):E454-E461. (Pubitemid 40110656)
14. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007;92(9):3490-3497. (Pubitemid 47435325)
15. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21(6):697-738. (Pubitemid 32113289)
16. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363(14):1341-1350.
17. O'Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol 2007;50(1):1-13. (Pubitemid 46963521)
18. Schaffer JE. Lipotoxicity: when tissues over-eat. Curr Opin Lipidol 2003;14(3):281-287.
19. van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008;117(1):43-51. (Pubitemid 350291180)
20. Kankaanpää M, Lehto HR, Pärkkä JP, et al. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab 2006;91(11):4689-4695. (Pubitemid 44833458)
21. Liu J, Fox CS, Hickson D, et al. Pericardial adipose tissue, atherosclerosis, and cardiovascular disease risk factors: the Jackson heart study. Diabetes Care 2010;33(7):1635-1639.
22. Wang TD, Lee WJ, Shih FY, et al. Relations of epicardial adipose tissue measured by multidetector computed tomography to components of the metabolic syndrome are region-specific and independent of anthropometric indexes and intraabdominal visceral fat. J Clin Endocrinol Metab 2009;94(2):662-669.
23. Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008;52(19):1574-1580.
24. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53(8):2087-2094. (Pubitemid 38970759)
25. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987;36(1):54-59. (Pubitemid 17016386)
26. Taksali SE, Caprio S, Dziura J, et al. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes 2008;57(2):367-371.
27. Yoshizumi T, Nakamura T, Yamane M, et al. Abdominal fat: standardized technique for measurement at CT. Radiology 1999;211(1):283-286. (Pubitemid 29161765)
28. Ross R, Léger L, Morris D, de Guise J, Guardo R. Quantification of adipose tissue by MRI: relationship with anthropometric variables. J Appl Physiol 1992;72(2):787-795.
29. Machann J, Thamer C, Schnoedt B, et al. Standardized assessment of whole body adipose tissue topography by MRI. J Magn Reson Imaging 2005;21(4):455-462. (Pubitemid 40446442)
30. Seidell JC, Bakker CJ, van der Kooy K. Imaging techniques for measuring adipose-tissue distribution-a comparison between computed tomography and 1.5-T magnetic resonance. Am J Clin Nutr 1990;51(6):953-957.
31. Kullberg J, Karlsson AK, Stokland E, Svensson PA, Dahlgren J. Adipose tissue distribution in children: automated quantification using water and fat MRI. J Magn Reson Imaging 2010;32(1):204-210.
32. Armao D, Guyon JP, Firat Z, Brown MA, Semelka RC. Accurate quantification of visceral adipose tissue (VAT) using water-saturation MRI and computer segmentation: preliminary results. J Magn Reson Imaging 2006;23(5):736-741.
33. Donnelly LF, O'Brien KJ, Dardzinski BJ, et al. Using a phantom to compare MR techniques for determining the ratio of intraabdominal to subcutaneous adipose tissue. AJR Am J Roentgenol 2003;180(4):993-998. (Pubitemid 36363039)
34. Huang TY, Chung HW, Wang FN, Ko CW, Chen CY. Fat and water separation in balanced steady-state free precession using the Dixon method. Magn Reson Med 2004;51(2):243-247.
35. Rijzewijk LJ, van der Meer RW, Smit JW, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008;52(22):1793-1799.
36. Schwenzer NF, Machann J, Schraml C, et al. Quantitative analysis of adipose tissue in single transverse slices for estimation of volumes of relevant fat tissue compartments: a study in a large cohort of subjects at risk for type 2 diabetes by MRI with comparison to anthropometric data. Invest Radiol 2010;45(12):788-794.
37. Pouliot MC, Després JP, Nadeau A, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992;41(7):826-834.
38. Machann J, Thamer C, Stefan N, et al. Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes. Radiology 2010;257(2):353-363.
39. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003;115(Suppl 8A):37S-41S.
40. Park HS, Lee K. Greater beneficial effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic syndrome: a study of weight reduction programmes in subjects with visceral and subcutaneous obesity. Diabet Med 2005;22(3):266-272. (Pubitemid 40313852)
41. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-2497.
42. Lafontan M, Girard J. Impact of visceral adipose tissue on liver metabolism. Part I: heterogeneity of adipose tissue and functional properties of visceral adipose tissue. Diabetes Metab 2008;34(4 Pt 1):317-327.
43. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40(6):1387-1395. (Pubitemid 39657013)
44. Starley BQ, Calcagno CJ, Harrison SA. Non-alcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51(5):1820-1832.
45. Cassidy FH, Yokoo T, Aganovic L, et al. Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. RadioGraphics 2009;29(1):231-260.
46. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288(2):E462-E468. (Pubitemid 40110657)
47. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of Fatty liver. Endocr Rev 2008;29(7):939-960.
48. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28(1):27-38.
49. Musso G, Gambino R, Bo S, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 2008;31(3):562-568.
50. Sevastianova K, Hakkarainen A, Kotronen A, et al. Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling. Radiology 2010;256(2):466-473.
51. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010;254(1):47-66.
52. De Minicis S, Bataller R, Brenner DA. NADPH oxidase in the liver: defensive, offensive, or fibrogenic? Gastroenterology 2006;131(1):272-275.
53. Noren B, Dahlqvist O, Lundberg P, et al. Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy. Eur J Radiol 2008;66(2):313-320. (Pubitemid 351626396)
54. Sharma R, Sinha S, Danishad KA, et al. Investigation of hepatic gluconeogenesis pathway in non-diabetic Asian Indians with non-alcoholic fatty liver disease using in vivo ((31)P) phosphorus magnetic resonance spectroscopy. Atherosclerosis 2009;203(1):291-297.
55. Schmid AI, Szendroedi J, Chmelik M, Krssák M, Moser E, Roden M. Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes. Diabetes Care 2011;34(2):448-453.
56. Rijzewijk LJ, van der Meer RW, Lubberink M, et al. Liver fat content in type 2 diabetes: relationship with hepatic perfusion and substrate metabolism. Diabetes 2010;59(11):2747-2754.
57. Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010;254(2):393-400.
58. Lewis GF. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 1997;8(3):146-153. (Pubitemid 27290460)
59. Lusis AJ. Atherosclerosis. Nature 2000;407(6801):233-241.
60. Hayashi K, Naiki T. Adaptation and remodeling of vascular wall; biomechanical response to hypertension. J Mech Behav Biomed Mater 2009;2(1):3-19.
61. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318(20): 1315-1321.
62. Henry RM, Kostense PJ, Spijkerman AM, et al. Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation 2003;107(16):2089-2095. (Pubitemid 36532189)
63. Safar ME, Thomas F, Blacher J, et al. Metabolic syndrome and age-related progression of aortic stiffness. J Am Coll Cardiol 2006;47(1):72-75. (Pubitemid 43005167)
64. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005;46(1):200-204. (Pubitemid 40946514)
65. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002;106(16):2085-2090. (Pubitemid 35192814)
66. Grotenhuis HB, Westenberg JJ, Steendijk P, et al. Validation and reproducibility of aortic pulse wave velocity as assessed with velocity-encoded MRI. J Magn Reson Imaging 2009;30(3):521-526.
67. Nelson AJ, Worthley SG, Cameron JD, et al. Cardiovascular magnetic resonance-derived aortic distensibility: validation and observed regional differences in the elderly. J Hypertens 2009;27(3):535-542.
68. Westenberg JJ, de Roos A, Grotenhuis HB, et al. Improved aortic pulse wave velocity assessment from multislice two-directional in-plane velocity-encoded magnetic resonance imaging. J Magn Reson Imaging 2010;32(5):1086-1094.
69. Groenink M, de Roos A, Mulder BJ, Spaan JA, van der Wall EE. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol 1998;82(2):203-208. (Pubitemid 28337732)
70. Bramwell JC, Hill AV. The velocity of the pulse wave in man. Proc R Soc Lond 1922;93(652):298-306.
71. Kimoto E, Shoji T, Shinohara K, et al. Preferential stiffening of central over peripheral arteries in type 2 diabetes. Diabetes 2003;52(2):448-452. (Pubitemid 36173202)
72. van der Meer RW, Diamant M, Westenberg JJ, et al. Magnetic resonance assessment of aortic pulse wave velocity, aortic distensibility, and cardiac function in uncomplicated type 2 diabetes mellitus. J Cardiovasc Magn Reson 2007;9(4):645-651. (Pubitemid 46956896)
73. Fielden SW, Fornwalt BK, Jerosch-Herold M, Eisner RL, Stillman AE, Oshinski JN. A new method for the determination of aortic pulse wave velocity using cross-correlation on 2D PCMR velocity data. J Magn Reson Imaging 2008;27(6):1382-1387. (Pubitemid 351770693)
74. Hardy CJ, Bolster BD Jr, McVeigh ER, Iben IE, Zerhouni EA. Pencil excitation with interleaved Fourier velocity encoding: NMR measurement of aortic distensibility. Magn Reson Med 1996;35(6):814-819. (Pubitemid 26172615)
75. Taviani V, Patterson AJ, Graves MJ, et al. Accuracy and repeatability of Fourier velocity encoded M-mode and two-dimensional cine phase contrast for pulse wave velocity measurement in the descending aorta. J Magn Reson Imaging 2010;31(5):1185-1194.
76. Roes SD, Alizadeh Dehnavi R, Westenberg JJ, et al. Assessment of aortic pulse wave velocity and cardiac diastolic function in subjects with and without the metabolic syndrome: HDL cholesterol is independently associated with cardiovascular function. Diabetes Care 2008;31(7):1442-1444.
77. Rider OJ, Tayal U, Francis JM, et al. The effect of obesity and weight loss on aortic pulse wave velocity as assessed by magnetic resonance imaging. Obesity (Silver Spring) 2010;18(12):2311-2316.
78. Mahmud A, Feely J. Antihypertensive drugs and arterial stiffness. Expert Rev Cardiovasc Ther 2003;1(1):65-78.
79. Kim SG, Ryu OH, Kim HY, et al. Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. Eur J Endocrinol 2006;154(3):433-440.
80. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007;11(9):1143-1160. (Pubitemid 47532862)
81. Roes SD, Westenberg JJ, Doornbos J, et al. Aortic vessel wall magnetic resonance imaging at 3.0 Tesla: a reproducibility study of respiratory navigator gated free-breathing 3D black blood magnetic resonance imaging. Magn Reson Med 2009;61(1):35-44.
82. Alizadeh Dehnavi R, Doornbos J, Tamsma JT, et al. Assessment of the carotid artery by MRI at 3T: a study on reproducibility. J Magn Reson Imaging 2007;25(5): 1035-1043. (Pubitemid 46697575)
83. Fayad ZA, Fuster V. The human high-risk plaque and its detection by magnetic resonance imaging. Am J Cardiol 2001;88(2A):42E-45E. (Pubitemid 32721985)
84. Chen K, Lindsey JB, Khera A, et al. Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study. Diab Vasc Dis Res 2008;5(2):96-101. (Pubitemid 351839280)
85. Chan SK, Jaffer FA, Botnar RM, et al. Scan reproducibility of magnetic resonance imaging assessment of aortic atherosclerosis burden. J Cardiovasc Magn Reson 2001;3(4):331-338. (Pubitemid 34031565)
86. Cai JM, Hatsukami TS, Ferguson MS, Small R, Polissar NL, Yuan C. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation 2002;106(11): 1368-1373. (Pubitemid 35013040)
87. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004; 126(50):16316-16317. (Pubitemid 40081918)
88. McAteer MA, Schneider JE, Ali ZA, et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol 2008;28(1):77-83.
89. Tang TY, Howarth SP, Miller SR, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009;53(22):2039-2050.
90. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001;104(3): 249-252. (Pubitemid 32666942)
91. Lima JA, Desai MY, Steen H, Warren WP, Gautam S, Lai S. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 2004;110(16):2336-2341. (Pubitemid 39407336)
92. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 1995;26(5):1133-1139.
93. Nesto RW, Kowalchuk GJ. The ischemic cascade: temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia. Am J Cardiol 1987;59(7):23C-30C. (Pubitemid 17047959)
94. Perseghin G, Lattuada G, De Cobelli F, et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008;47(1):51-58. (Pubitemid 351171041)
95. Celentano A, Vaccaro O, Tammaro P, et al. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol 1995;76(16):1173-1176.
96. von Bibra H, St John Sutton M. Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia 2010;53(6):1033-1045.
97. Ng AC, Auger D, Delgado V, et al. Quantification of diffuse myocardial fibrosis by cardiac magnetic resonance contrast-enhanced T1 mapping is associated with subclinical myocardial dysfunction in diabetic heart disease. Circulation 2010; 122(21-MeetingAbstracts):A14588.
98. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echo-cardiography. Eur J Echocardiogr 2009; 10(2):165-193.
99. Appleton CP, Jensen JL, Hatle LK, Oh JK. Doppler evaluation of left and right ventricular diastolic function: a technical guide for obtaining optimal flow velocity recordings. J Am Soc Echocardiogr 1997;10(3):271-292. (Pubitemid 127789859)
100. Bella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation 2002;105(16):1928-1933. (Pubitemid 34437620)
101. Engels G, Müller E, Reynen K, Wilke N, Bachmann K. Evaluation of left ventricular inflow and volume by MR. Magn Reson Imaging 1993;11(7):957-964.
102. Kayser HW, Stoel BC, van der Wall EE, van der Geest RJ, de Roos A. MR velocity mapping of tricuspid flow: correction for through-plane motion. J Magn Reson Imaging 1997;7(4):669-673. (Pubitemid 28365615)
103. Westenberg JJ, Roes SD, Ajmone Marsan N, et al. Mitral valve and tricuspid valve blood flow: accurate quantification with 3D velocity-encoded MR imaging with retrospective valve tracking. Radiology 2008;249(3):792-800.
104. Brandts A, Bertini M, van Dijk EJ, et al. Left ventricular diastolic function assessment from three-dimensional three-directional velocity-encoded MRI with retrospective valve tracking. J Magn Reson Imaging 2011;33(2):312-319.
105. Westenberg JJ, Lamb HJ, van der Geest RJ, et al. Assessment of left ventricular dyssynchrony in patients with conduction delay and idiopathic dilated cardiomyopathy: head-to-head comparison between tissue doppler imaging and velocity-encoded magnetic resonance imaging. J Am Coll Cardiol 2006;47(10):2042-2048.
106. Marsan NA, Westenberg JJ, Tops LF, et al. Comparison between tissue Doppler imaging and velocity-encoded magnetic resonance imaging for measurement of myocardial velocities, assessment of left ventricular dyssynchrony, and estimation of left ventricular filling pressures in patients with ischemic cardiomyopathy. Am J Cardiol 2008;102(10):1366-1372.
107. Rijzewijk LJ, van der Meer RW, Lamb HJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 2009;54(16):1524-1532.
108. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115(25):3213-3223. (Pubitemid 47012236)
109. Sharma S, Adrogue JV, Golfman L, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004;18(14):1692-1700. (Pubitemid 39463708)
110. van der Meer RW, Doornbos J, Kozerke S, et al. Metabolic imaging of myocardial triglyceride content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology 2007;245(1):251-257. (Pubitemid 47417809)
111. Reingold JS, McGavock JM, Kaka S, Tillery T, Victor RG, Szczepaniak LS. Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. Am J Physiol Endocrinol Metab 2005;289(5):E935-E939. (Pubitemid 41504396)
112. McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007;116(10):1170-1175. (Pubitemid 47360218)
113. Lamb HJ, Doornbos J, den Hollander JA, et al. Reproducibility of human cardiac 31PNMR spectroscopy. NMR Biomed 1996;9(5):217-227.
114. Sacks HS, Fain JN. Human epicardial adipose tissue: a review. Am Heart J 2007;153(6):907-917. (Pubitemid 46809849)
115. Mazurek T, Zhang L, Zalewski A, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003;108(20):2460-2466. (Pubitemid 37444406)
116. Nelson AJ, Worthley MI, Psaltis PJ, et al. Validation of cardiovascular magnetic resonance assessment of pericardial adipose tissue volume. J Cardiovasc Magn Reson 2009;11:15.
117. Flüchter S, Haghi D, Dinter D, et al. Volumetric assessment of epicardial adipose tissue with cardiovascular magnetic resonance imaging. Obesity (Silver Spring) 2007;15(4):870-878. (Pubitemid 46740962)
118. Iozzo P, Lautamaki R, Borra R, et al. Contribution of glucose tolerance and gender to cardiac adiposity. J Clin Endocrinol Metab 2009;94(11):4472-4482.
119. Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab 2011;22(11):450-457.
120. Miao C, Chen S, Ding J, et al. The association of pericardial fat with coronary artery plaque index at MR imaging: The Multi-Ethnic Study of Atherosclerosis (MESA). Radiology 2011;261(1):109-115.
121. Jonker J, Snel M, Hammer S, et al. Longterm diet-induced, tissue-specific changes in (non)adipose triglyceride stores in obese patients with type 2 diabetes mellitus. J Cardiovasc Magn Reson 2011;13(Suppl 1):P352.
122. Jonker JT, Lamb HJ, van der Meer RW, et al. Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95(1):456-460.
123. Fox CS, Gona P, Hoffmann U, et al. Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function: the Framingham Heart Study. Circulation 2009;119(12):1586-1591.
124. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15(4):827-832. (Pubitemid 20101575)
125. Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 2000;36(4):1253-1260.
126. Keelan PC, Bielak LF, Ashai K, et al. Longterm prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation 2001;104(4):412-417. (Pubitemid 32678270)
127. Wong ND, Hsu JC, Detrano RC, Diamond G, Eisenberg H, Gardin JM. Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events. Am J Cardiol 2000;86(5):495-498.
128. Wong ND, Sciammarella MG, Polk D, et al. The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. J Am Coll Cardiol 2003;41(9):1547-1553. (Pubitemid 36543374)
129. Lim S, Shin H, Lee Y, et al. Effect of metabolic syndrome on coronary artery stenosis and plaque characteristics as assessed with 64-detector row cardiac CT. Radiology 2011;261(2):437-445.
130. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343(20):1445-1453.
131. Klein C, Nekolla SG, Bengel FM, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation 2002;105(2):162-167. (Pubitemid 34084313)
132. Rogers WJ Jr, Kramer CM, Geskin G, et al. Early contrast-enhanced MRI predicts late functional recovery after reperfused myocardial infarction. Circulation 1999;99(6):744-750. (Pubitemid 29083013)
133. DeLuca AJ, Kaplan S, Aronow WS, et al. Comparison of prevalence of unrecognized myocardial infarction and of silent myocardial ischemia detected by a treadmill exercise sestamibi stress test in patients with versus without diabetes mellitus. Am J Cardiol 2006;98(8):1045-1046. (Pubitemid 44486143)
134. Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008;118(10):1011-1020.
135. Ebeling Barbier C, Bjerner T, Hansen T, et al. Clinically unrecognized myocardial infarction detected at MR imaging may not be associated with atherosclerosis. Radiology 2007;245(1):103-110.
136. Barbier CE, Nylander R, Themudo R, et al. Prevalence of unrecognized myocardial infarction detected with magnetic resonance imaging and its relationship to cerebral ischemic lesions in both sexes. J Am Coll Cardiol 2011;58(13):1372-1377.
137. Burgess DC, Hunt D, Li L, et al. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J 2010;31(1):92-99.
138. Chung YE, Park MS, Park YN, et al. Hepatocellular carcinoma variants: radiologicpathologic correlation. AJR Am J Roentgenol 2009;193(1):W7-W13.
139. Kim RJ, Shah DJ, Judd RM. How we perform delayed enhancement imaging. J Cardiovasc Magn Reson 2003;5(3):505-514. (Pubitemid 36859434)